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Abstract
Background: The innate immune system employs several receptor families that form the basis of sensing
pathogen-associated molecular patterns. NOD (nucleotide-binding and oligomerization domain) like receptors
(NLRs) comprise a group of cytosolic proteins that trigger protective responses upon recognition of intracellular
danger signals. NOD2 displays a tandem caspase recruitment domain (CARD) architecture, which is unique within
the NLR family.
Findings: Here, we report a novel alternative transcript of the NOD2 gene, which codes for a truncated tandem
CARD only protein, called NOD2-C2. The transcript isoform is highest expressed in leucocytes, a natural barrier
against pathogen invasion, and is strictly linked to promoter usage as well as predominantly to one allele of the
single nucleotide polymorphism rs2067085. Contrary to a previously identified truncated single CARD NOD2
isoform, NOD2-S, NOD2-C2 is able to activate NF-B in a dose dependent manner independently of muramyl
dipeptide (MDP). On the other hand NOD2-C2 competes with MDPs ability to activate the NOD2-driven NF-B
signaling cascade.
Conclusion: NOD2 transcripts having included an alternative exon downstream of exon 3 (exon 3a) are the
endogenous equivalents of a previously described in vitro construct with the putative protein composed of only
the two N-terminal CARDs. This protein form (NOD2-C2) activates NF-B independent of an MDP stimulus and is a
potential regulator of NOD2 signaling.
Background
The innate immune system uses several molecules that
sense pathogen-associated molecular patterns (PAMPs)
including Toll-like, RIG-1 (retinoic acid inducible gene
protein 1)-like and the NOD (nucleotide-binding and
oligomerization domain)-like receptors (NLRs) to trigger
a protective response against intracellular danger signals,
e.g. cytoinvasive pathogens. The NLRs family consists of
more than 20 related members defined by a tripartite
structure consisting of: (i) a variable N-terminal protein-
protein interaction domain, defined by the caspase
recruitment domain (CARD), pyrin domain (PYD), or
the baculovirus inhibitor domain (BIR); (ii) a centrally
located NOD domain facilitating self-oligomerization
during activation [1], and (iii) a C-terminal leucine-rich
repeat (LRR) responsible for binding/detecting of
PAMPs. The N-terminal effector binding domains are
essential elements of the NLRs to elicit a signal subse-
quent to NLR activation. In case of NOD1 and NOD2
(CARD15), the N-terminal domain is formed by a single
or a tandem CARD, respectively. Both are pivotal for
the induction of pro-inflammatory pathways in response
to bacteria by inducing signaling pathways via NF-B
(nuclear factor kappa B) or MAPK (mitogen-activated
protein kinases) and recognize bacterial cell wall compo-
nents derived from peptidoglycan (PGN). NOD1 activity
is triggered by g-D-glutamyl-meso-diaminopimelic acid
(meso-DAP) [2,3]. In contrast, NOD2 is activated by
muramyl dipeptide (MDP), a peptidogylcan motif pre-
sent in all Gram-positive and -negative bacteria [4,5].
Initial biochemical characterization of NOD1/2 revealed
that both proteins induce NF-B activation in a Toll-
like receptor-independent f a s h i o n[ 6 ] .U p o nl i g a n d
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and self-oligomerization. This process is followed by
recruitment and activation of the serine threonine
kinase RIP2 (receptor interacting protein 2) via homo-
philic CARD/CARD interaction, which is essential for
the activation of NF-B and MAPKs [7-9].
Despite insufficient expression of endogenous proteins
hampering their analysis, in vitro enforced protein
expression of NLRs has shed some light on the intracel-
lular distribution of these molecules. In addition to their
preponderant cytosolic localization, NOD1/2 were also
found to be associated with the plasma membrane
[10-14]. The plasma membrane association of NOD2
has been linked to activation of downstream signaling
events since point-mutations of NOD2 interfering with
their membrane association capacity resulted in blunted
NOD2-mediated NF-B activation [10]. However, the
latter studies are difficult to interpret as the same muta-
tions also interfered with MDP recognition [12]. These
genetic variants in NOD2 have been associated with sus-
ceptibility for Crohn’s disease (CD), a chronic inflamma-
tory bowel disorder. Three major CD-associated
polymorphisms (Arg702Trp, Gly908Arg and Leu1007-
sinsC) are located in or near the LRR domain and are
associated with a decreased NOD2 activation by MDP
[15-18]. Moreover, a recent genome-wide association
study of Leprosy identified NOD2 sequence variants to
be significantly associated with affected status [19].
It has been shown that proinflammatory stimuli, such
as TNF-a,I F N - g and lipopolysaccharide (LPS) activate
NOD2 gene expression in intestinal epithelial cell lines
and primary intestinal epithelial cells as well as monocy-
tic HL-60 cells [20,21]. This up-regulation is at least in
part dependent on the binding of NF-Bt oap r o x i m a l
B-binding element (-26) of a NOD2 promoter region
in front of the canonical first exon. Rosenstiel and col-
leagues [22] identified two novel exons of the NOD2
gene (designated exon 1a and 1b), which are spliced to
the canonical exon 2 and constitute the 5′-untranslated
region of two alternative transcripts (i.e. exon 1a/1b/2
and exon 1a/2). These transcript isoforms are abun-
dantly expressed and seem to comprise the majority of
NOD2 transcripts under physiological conditions.
Further studies on NOD2 mRNA splicing revealed a
short isoform, NOD2-S, caused by skipping of the third
exon and a subsequent premature stop codon in exon 4
[22,23]. The truncated protein is restricted to only one
of its unique tandem CARD domains and has been
shown to be an endogenous inhibitor of the NOD2/
receptor-interacting protein kinase 2 (RIP2)-induced sig-
naling pathway [22]. NOD2-S competes with the down-
stream target of NOD2, RIP2, for binding of NOD2.
This inhibits the signaling cascade within the NOD2-
induced activation of the NF-B driven immune
response. NOD2-S induced expression and secretion of
the pro-inflammatory cytokine IL-8 and NOD2/RIP2-
dependent IL-1b maturation. This suggests an important
role of the CARD-only containing isoform in the modu-
lation of NOD2/RIP2 signaling events [22]. In contrast,
Leung et al. and Ogura et al. reported that an artificial
truncated isoform of NOD2 comprising both CARDs is
able to activate NF-B independent of a MDP stimula-
tion [23,24]. It is still an unresolved issue why NOD2
exhibits a tandem CARD motif. However, our results
indicate a differential role of single and tandem CARD
domains in NLRs.
In this report, we present an endogenous NOD2 alter-
native transcript coding for a protein containing the two
CARDs only, NOD2-C2. We identified this splicing
event to be both promoter as well as single nucleotide
polymorphism (SNP) dependent and initially verified
functional consequences with respect to the divergent
roles of single and tandem CARD isoforms in NF-B-
induced inflammatory immune response.
Material and methods
Cell culture
Human EBV transformed lymphoblastoid cell lines
(LCLs) GM10847, GM10854, GM10854, GM12760,
GM12864, GM15215, GM15324, GM15386, GM18502,
GM18552, GM18858, GM18972, GM19140, and
GM19204 were obtained from the Coriell Cell Reposi-
tory (Camden, USA). C0766 and the chimpanzee cell
line EB176(JC) were from European Collection of Cell
Cultures (ECACC, Salisbury, UK). Cells were cultured at
37°C in RPMI 1640 medium (Gibco, Eggenstein, Ger-
many) supplemented with 15% FCS (Gibco) and 2 mM
L-Glutamine (Gibco) in a 5% CO2 atmosphere and 95%
humidity.
Nucleic acids
Genomic DNA was isolated from the indicated cell lines
using the Blood & Cell Culture DNA Mini Kit (Qiagen,
Hilden, Germany) according to standard protocols.
Total RNA was isolated from the cell lines using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) at three
subsequent days according to manufacturer’sp r o t o c o l .
cDNA first strand synthesis was performed with “Sprint
RT Complete-Random Hexamer” cDNA synthesis kit
(Clontech-Takara Bio Europe, Saint-Germain-en-Laye,
France) following the manufacturer’s recommendations.
5 μg total RNA were used for reverse transcription.
Human tissue cDNAs were from Clontech (MTC Multi-
ple Tissue cDNA Panels).
PCR amplification and sequence analysis
PCR was performed with “BioMix white” (Bioline,
Randolph, USA) according to manufacturer’sp r o t o c o li na
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or 1 μl from human cDNA tissue panels (Clontech) and
10 pmol primer. In general, PCR reaction started with an
initial denaturation at 93°C for 1 min, followed by 5 cycles
of 30 sec denaturation (95°C), 30 sec annealing tempera-
ture temperature 1 and 1 min elongation at 72°C. Addi-
tional 25 cycles were performed with annealing
temperature 2 followed by a final elongation of 20 min at
72°C. Primers and corresponding annealing temperatures
1/2 were as follows: quantNOD2ex24.f (5′-Fam-ATTGT-
CAGGAGGCTCCACAG-3′) and quantNOD2ex24.r
(5′-TGTCCGCATCGTCATTGAG-3′)a t5 7 ° C / 5 9 ° C ,
NOD2ex24.f (5′-ATTGTCAGGAGGCTCCACAG-3′)a n d
NOD2ex24.r (5′-TGTCCGCATCGTCATTGAG-3′)a t5 7 °
C/59°C, NOD2ex23.f (5′- ATTGTCAGGAGGCTCCA-
CAG-3′) and NOD2ex23.r (5′-TAGAAGGAAGGCAGC-
CAATC-3′) at 56°C/58°C, NOD2ex23a.f (5′-GGTACTT
GGGCCTGTCAGAA-3′) and NOD2ex23a.r (5′-AAACCT
GGGTCCACCATACA-3′) at 55°C/57°C, NOD2ex3a4.f
(5′-TGTATGGTGGACCCAGGTTT-3′) and NOD2ex3a4.
r( 5 ′-TGTCCGCATCGTCATTGAG-3′) at 56°C/58°C,
GAPDH.f (5′-AGGGCTGCTTTTAACTC-3′)a n dG A P
DH.r (5′-GCTTCACCACCTTCTTG-3′) at 53°C/55°C as
well as rs2067085.f (5′-CAGCCATGTGGAGAACATGC-
3′) and rs2067085.r (5′-GTTCATGGTGGTACAGCAGC-
3′) at 53°C/55°C. PCR products of the NOD2 locus were
sequence analyzed using the ABI3730xl platform (Applied
Biosystems, Foster City, USA).
To analyse the 5′-end of NOD2 exon 3a specific tran-
scripts we performed 5′-rapid amplification of cDNA
ends (RACE) on human leukocyte cDNA. Nested PCR
was performed with “BioMix white” (Bioline) according
to manufacturer’s protocol in a total volume of 50 μl
including 3 μl human leukocyte Marathon® ready cDNA
(Clontech) and 10 pmol primer. Marathon® ready cDNA
specific primers (AP1, AP2) were purchased from Clon-
tech. Gene specific primers (GSP) were from Metabion
(Martinsried, Germany). In general, PCR reaction started
with an initial denaturation at 93°C for 1 min, followed
by 5 cycles of 30 sec denaturation (95°C), 30 sec anneal-
ing temperature 1 and 90 sec elongation at 72°C. Addi-
tional 30 cycles were performed with annealing
temperature 2 followed by a final elongation of 20 min
at 72°C. Nested PCR was performed analogous using
3 μl of PCR product as template. Primers and corre-
sponding annealing temperatures (1/2) were as follows:
GSP1 (5′-AAACCTGGGTCCACCATACA-3′, 55°C/57°
C) and AP1 (Marathon® cDNA amplification Kit, Clon-
tech) as well as GSP2 (5′-CCATTTAGCCTTTCTGGG
CCTCAGTTCTC-3′, 65°C/67°C) and AP2 (Marathon®
cDNA amplification Kit, Clontech). PCR amplicons were
cloned into pCR2.1TOPO using Topo TA Cloning® Kit
(Invitrogen, Karlsruhe, Germany) and subsequently
sequenced.
Capillary electrophoresis - laser induced fluorescence
analysis
PCR amplification was carried out with 5′-6-carboxy-
fluorescein (FAM)-labeled forward or reverse primers
(quantNOD2ex24.f/r). The FAM-labeled PCR products
were appropriately diluted (up to 1/40) and 1 μlo ft h e
diluted sample was supplemented with 10 μlf o r m a m i d e
(Roth, Karlsruhe, Germany) and 0.5 μl of GeneScan
ROX 500 (Applied Biosystems) size standard. The mix-
ture was denatured at 94°C for 3 min, and subsequently
cooled on ice. The denatured products were then sepa-
rated on an ABI3730xl capillary sequencer and analyzed
using Gene Mapper 4.0 software (Applied Biosystems).
The amount of each isoform within a PCR reaction was
calculated by the area under the curve. NOD2-C2 per-
cent fraction was calculateda se x o n3a n d3 ai n c l u s i o n
versus the sum of all transcripts spanning the exons 2-4.
All values are given as mean ± standard deviation of
PCRs on three independent RNA isolations.
NOD2-C2 expression construct
The N-terminal FLAG-tagged NOD2-C2 expression con-
struct pcDNA3.1-NOD2-C2 was obtained by overlapping
extension PCR and cloned into the pcDNA3.1(+) (Invitro-
gen, Karlsruhe, Germany) expression plasmid. Therefore,
four PCR products were amplified under standard PCR
conditions using the following primers: NOD2ex1EcoRI.f3
(5′-GAATTCAGGAGGAAAGAGCAAGTGTC-3′)a n d
NOD2ex2ext.r (5′-CTTGTAACCTTGATACCAACCA
TTTCACAACCCGGAGAAT-3′), HBBin1.f (5′-GTTGG
TATCAAGGTTACAAG-3′) and HBBin1FLAG.rn
(5′-CTTATCATCATCATCCTTGTAATCCTAAGGGT
GGGAAAATAGAC-3′), NOD2ex2ext.fn (5′-ATTA-
CAAGGATGATGATGATAAGTGCTCGCAGGAGGC
TTT TCA-3′) and NOD2ex3.r2 (5′-CCAATGGGACTGG-
TAATTCC-3′) as well as NOD2in3df (5′-AGGCTGCTT-
GATCTTGCCAC-3′) and NOD2ex3aEcoRI.r (5′-GAATT
CAACCTGGGTCCACCATAC-3′). NOD2 exons 1-2 and
2-3 were amplified from cDNA of EBV-transformed
human B-lymphocyte cells, NOD2 exons 3-3a from
human testis cDNA (human MTC cDNA panel from
Clontech) and HBB intron 1 from human genomic DNA
(human genomic DNA pool from Roche, Mannheim, Ger-
many). PCR products were subcloned with Topo TA
Cloning® (Invitrogen). Linker PCR was performed with
Pfu Turbo Polymerase (Stratagen) and the cloned PCR
fragments. Primers were used as previously listed, except
HBBin1ext.f (5′-ATTCTCCGGGTTGTGAAATGGTTG
GTATCAAGGTTACAAG-3′) instead of HBBin1.f and
HBBin1FLAGext.rn (5′-TGAAAAGCC TCCTGCGAG-
CACTTATCATCATCATCCTTGTAA TC-3′) instead of
HBBin1FLAG.rn. Overlapping extension PCR was per-
formed after addition of extra Pfu Turbo Polymerase and
dNTPs to the mixture of all 4 linker PCR products. The
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for an amplification of the whole NOD2-C2 expression
construct with flanking primers (NOD2ex1EcoRI.f3 and
NOD2ex3aEcoRI.r) using “BioMix white” (Bioline) accord-
ing to manufacturer’s protocol. PCR products were again
subcloned with Topo TA Cloning® (Invitrogen) and subse-
quently cloned into pcDNA3.1(+) with EcoRI and T4-
DNA ligase (both from Fermentas, St. Leon-Rot, Ger-
many) according to the manufacturer’s instructions. All
clones and constructs were sequence-verified with
ABI3730xl.
NF-B activation assay
For quantification of NF-B activity, transient transfec-
tion was performed using Fugene 6™ (Roche) according
to the manufacturer’s manual. One day before transfec-
tion human embryonal kidney HEK293 cells (ACC305,
German Collection of Microorganisms and Cell Cul-
tures, DSMZ Braunschweig, Germany) were seeded at a
d e n s i t yo f2×1 0
4/100 μlo na9 6 - w e l lp l a t ea n dc u l -
tured in Dulbecco’s MEM medium (PAA Laboratories,
Paschberg, Austria) supplemented with 10% fetal calf
serum (FCS). Conditions for growth were 5% CO2 atmo-
sphere and 95% humidity at 37°C. At the following day
cells were cotransfected with pcDNA3.1empty vector
(mock-control) and pcDNA3.1-NOD2 (a kind gift from
G. Nunez, University of Michigan, Ann Arbor) or
pcDNA3.1-NOD2-C2 together with 15 ng 3X NF-B-
luciferase reporter plasmid (Clontech) and 5 ng pRL-TK
renilla reporter plasmid (Promega, Mannheim, Ger-
many). For normalization of transfection efficiency and
cell viability increasing concentrations of pcDNA3.1-
NOD2-C2 or pcDNA3.1-NOD2 and pcDNA3.1 empty
vector, respectively, up to a final concentration of 50 ng
of DNA per well were used. 24 h after transfection, cells
were stimulated with LD-MDP (10 μg/ml, Bacham) for
18 h. After incubation cells were washed in PBS and
lysed in 1X Passive Lysis Buffer (Promega). Dual Luci-
ferase Assay (DLA) was performed using the Dual Luci-
ferase® reporter assay system (Promega) and a
MicroLumatPlus Luminometer (Berthold, Bad Wildbad,
Germany). Each experiment was repeated independently
three times. The results for firefly luciferase activity
were normalized using the reference plasmid and
expressed as relative light units (RLU).
Immunofluorescence confocal-like microscopy
HEK293E and african green monkey kidney COS7 cells
(ATCC, Rockville, MD, USA) were seeded on sterile
poly-L-lysine coated coverslips and cultured in Dulbec-
co’s MEM medium (PAA Laboratories, Paschberg, Aus-
tria) supplemented with 10% fetal calf serum (FCS) at
5% CO2 atmosphere, 95% humidity and 37°C. Cells
were transfected after 24 h with Flag-NOD2-C2 using
Lipofectamine 2000 (Invitrogen) according to manufac-
turer’s instructions. After 48 h, cells were fixed and
stained according to a standardized protocol [25]. As
primary and secondary antibodies M2-anti-FLAG mono-
clonal mouse (F1804, Sigma-Aldrich, St. Louis, United
States) and Alexa Fluor 555 goat anti-mouse IgG
(A21424) from Invitrogen were used, respectively Con-
focal-like microscopy was performed on the Axiovert
200 microscopy system (Carl Zeiss, Jena, Germany).
Statistical analysis
Statistical significance (p-value) was calculated with
Sigma Plot 11.0 (Systat Software, Chicago, USA). Com-
parison of different groups of the NF-B activation
assay was performed with the “All Pairwise Multiple
Comparison Procedure” (Tukey Test). For comparing
unstimulated and MDP treated cells as well as for
expression data the Student’s t-test (t-test) was
employed. In case where the normality test (Shapiro
Wilks) failed, the Mann-Whitney Rank Sum Test
(MWRST) was applied.
Results
Identification and expression patterns of NOD2-C2
It has been shown that short NOD2 isoforms exhibit
divergent functions compared to NOD2. This includes
either NOD2-S [22] or its mutated forms associated
with susceptibility for Crohn’s disease [15,16] as well as
artificial ones consisting of both CARD domains [24].
So far, no evidence for endogenous NOD2 transcript
isoforms encoding for a truncated CARD-CARD protein
existed. Studying human lymphoblastoid cell lines
(LCLs), we identified a respective alternative transcript,
called NOD2-C2. It results from inclusion of a - so far
unknown - exon between the exons 3 and 4 (termed
3a; genomic coordinates: hg19, chr16:49,301,356-
49,301,428; Figure 1). Inclusion of exon 3a adds nine
amino acids (aas, 189-197) to the C-terminal part of the
encoded NOD2-C2 that differ to those at the respective
NOD2 position (see Additional file 1). For complemen-
tation of the second CARD only the aa positions 188-
193 are of relevance [24]. Although the respective aas
are altered in NOD2-C2, prediction of the secondary
protein structure [26] suggests a helix motif for the aas
182-197. The same motif has been predicted for the
related aas of NOD2 (208-227 aa). Therefore it is likely,
that complementation of NOD2-C2 s second CARD by
inclusion of exon 3a creates a domain with NOD2-like
functional capability. From a genetic point of view,
exon 3a resides in an interspersed MIRb repetitive ele-
ment. Both acceptor and donor are identical to the con-
sensi of other exonized ALUs and MIRs, respectively
[ 2 7 , 2 8 ] .T h es e q u e n c eo fe x o n3 ai s1 0 0 %c o n s e r v e d
in chimpanzee and NOD2-C2 transcripts are also
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Exon 3a containing transcripts are predominantly
expressed in leukocytes as well as in other tissues like
spleen, testis or placenta (Figure 2). Exon 3a inclusion
is coupled to the concomitant inclusion of exon 3 and
transcription initiation at exon 1a (nomenclature
according to [29]). Moreover, we screened human tissue
cDNA panels for allelic imbalance in NOD2-C2 tran-
scription and detected predominant expression from
the major allele of the synonymous coding SNP
rs2067085 (C, Ser 178) in exon 2 (Figure 3). Since
NOD2-C2 expression is coupled to exon 3a splicing
other potentially splice-regulatory SNPs in the coding
and flanking regions of exon 3a were checked. How-
ever, neither rs34133110 (exon 3a) nor rs2066842 (exon
4) showed signs of allelic imbalance. Moreover, since
exon 3a inclusion requires concomitant inclusion of
exon 3, we examined rs2067085 (exon 2) and
rs2066842 (exon 4) for association with exon 2-3-4 spli-
cing but found no correlation. Due to the unknown
rs2067085 allele frequencies (HapMaps CEU: C/G
0.612/0.388) of the used cDNA tissue panels, expression
of minor alleles may be underestimated by sequencing.
Therefore, we screened 14 human LCLs for rs2067085
genotype-specific differences in NOD2-C2 transcription
by quantitative RT-PCR spanning the exons 2-4 (Figure
4). Among the LCLs we identified 11/1 homozygous for
C and G, respectively, as well as 4 heterozygous cell
lines. Comparing all three rs2067085 genotypes, signifi-
cant differences in NOD2-C2 transcript expression were
observed. The homozygous G LCL showed the lowest
relative expression (0.49 ± 0.03%), whereas expression is
doubled in homozygous C LCLs (1.08 ± 0.09%; p =
0.005, WMRST). Heterozygous LCLs had an intermedi-
ate (0.81 ± 0.10%) expression significantly different
from those of homozygous G (p = 0.012, WMRST) and
C (p = 0.001, WMRST) individuals. Our results identi-
fied NOD2-C2 transcripts being 2-fold higher expressed
from the major allele of rs2067085 compared to the
minor one (Figure 4).
Figure 1 Schematic transcript and protein representation of NOD2 and its isoforms NOD2-S as well as NOD2-C2. The novel NOD2-C2
transcript contains an additional exon 3a highlighted in black. Contrary to NOD2-S, NOD2-C2 has a reconstructed second CARD domain, which
differs in the last 9 amino acid compared to exon 3-4 spliced NOD2.
Figure 2 Expression pattern of NOD2-C2 transcripts in human tissues.R T - P C Rs p e c i f i cf o rNOD2 exon 3a inclusion and GAPDH was
performed on human cDNA tissue panels.
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The ability of NOD2-C2 for activation of NF-Ba n d
subsequent downstream signaling was analyzed using a
dual-luciferase reporter assay system. HEK293 cells
expressing only very low levels of endogenous NOD2
[10,30] had been transfected with increasing amounts
(0-28 ng) of NOD2 or NOD2-C2 expression construct.
All experiments were additionally carried out in cells
stimulated with MDP (10 μg/ml), an activator of the
NOD2-dependent NF-B activity (Figure 5, black bars).
All values are given as relative luciferase activity com-
pared to the NOD2 construct (2 ng) without MDP sti-
mulation (Figure 5B). NOD2-C2 is able to stimulate
NF-B activity in a dose dependent manner (p < 0.05;
T u k e yT e s t ;F i g u r e5 A ) .T h ep r e s e n c eo fM D Pd i dn o t
affect the ability of NOD2-C2 to activate NF-B( F i g -
ure 5A). As a control, NOD2 also activates NF-B
(Figure 5B). In contrast to NOD2-C2 this activation is
not dose sensitive, rather turns into a steady-state
level. To evaluate the NOD2-dependent activation of
NF-B by NOD2-C2 a titration of the NOD2-C2 con-
struct against constant amounts of NOD2 (2 ng)
expression vector was performed. The activity of NF-
B remains constant independently of the NOD2-C2
plasmid amounts (Figure 5B). At the same time,
NOD2-C2 abolishes the stimulatory effect of MDP
onto NOD2-induced NF-B activation (2-fold; p =
0.001 for 0 ng NOD2-C2 construct) and leads to an
even decreased NF-B activity in a dose-dependent
manner (p < 0.05 for 20 ng and 28 ng NOD2-C2 con-
struct; Figure 5B).
NOD2-C2 is localized in the cytoplasm
The cellular localization of NOD2-C2 in african green
monkey kidney COS7 and human embryonic kidney
HEK293E cells was carried out by immuno-fluorescence
confocal-like microscopy. 24 h after transfection NOD2-
C2 was cytosol-localized (Figure 6). We could not detect
a general localization of NOD2-C2 at other cellular
compartments than the cytoplasm.
Figure 3 Predominant inclusion of NOD2 exon 3a from the rs2067085 C allele and concomitant splicing to exon 3. Sequencing of RT-
PCR amplicons from human leukocyte cDNA to elucidate the processing of the primary transcript in the regions of exons 2-3a and 3a-4 as well
as 2-3 and 3-4. Fluorescence traces are given for the SNP context in exon 2 (rs2067085, minor allele frequency 0.388), exon 3a (rs34133110) and
exon 4 (rs2066842, minor allele frequency 0.362). Line: primary transcript; boxes: exons, arrows: PCR primers; dotted lines: amplifiable region;
angulated lines: observed splice events.
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PCR spanning NOD2 exon 2-4 and calculated as percent fraction of exon 3a inclusion vs. all processed transcripts from this region. Values
represent the mean ± standard deviation of triplicate RNA isolations. Statistical significance (WMRST): * p < 0.05; ** p < 0.01.
Figure 5 MDP-independent activation of NF-B by NOD2-C2. Relative NF-B activity was measured using a luciferase-based NF-B reporter
assay. HEK293 cells were cotransfected with NOD2-C2 (A), NOD2 or NOD2-C2/NOD2 (B) expression constructs and dual-lucifease reporter
plasmid. 10 μg/ml MDP were used to stimulate NOD2-mediated NF-B activation. Relative luciferase activity (compared to NOD2 (2ng) without
MDP stimulation) is plotted against NOD2 and/or NOD2-C2 plasmid amounts. Values represent the mean ± standard deviation of triplicate
cultures. Statistically significant differences are marked by asterisk * p < 0.05; ** p < 0.01.
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Several studies on NOD2 paid attention to its functional
domains by creating truncated isoforms and found
remarkable differences in their potential to activate NF-
B compared to wild type [24,30]. Beside transcripts
carrying CD-associated polymorphisms (Arg702Trp,
Gly908Arg and Leu1007sinsC) [15-18] only the alterna-
tive splice isoform NOD2-S and LRR-modifying exon
skipping have been found to be in vivo detectable varia-
tions [15-18,22,23] with a potential regulatory input in
NOD2 signaling. This is surprising, since Leung and col-
leagues found a large set of alternative splicing events in
a detailed analysis of NOD2 transcripts [23]. As far as
variations in the NOD or LRR domains are almost loss
of function events, it turned out that the number of
CARDs in CARD-only isoforms like NOD2-S seems to
be critical for acting as positive or negative regulators of
CARD-dependent caspase- or NF-B-signaling
pathways.
Our analysis revealed a novel NOD2 alternative tran-
script, NOD2-C2, coding for a unique tandem CARD
feature. We observed that in vitro (i) NOD2-C2 alone
interferes with the activation of NF-B in a dose depen-
dent manner, which is quite in contrast to NOD2-S that
inhibits NF-B activation, and (ii) NOD2-C2 in combi-
nation with NOD2 abolishes the stimulatory effect of
MDP. The first finding is in agreement with an initial
study by Ogura et al. in which it was shown that both
CARDs of NOD2 are essential for RIP2 recruitment
during induced proximity signaling and that neither the
first nor the second CARD alone are able to interact
with RIP2 [24]. This unique feature of the NOD2/RIP2
interaction has not yet been fully resolved on the struc-
tural level, because other RIP2-interacting proteins, pos-
sess only a single CARD domain (e.g. NOD1, bcl10, and
caspase-1). The ability of NOD2-S to bind RIP2 sheds
further light on the complexity of this interaction,
because NOD2-S exhibits only 54 out of 93 amino acids
of NOD2s second CARD. Nevertheless, this is sufficient
to mediate the attachment of RIP2, but not the subse-
quent NF-B activation. Thus the NOD2-S/RIP2 bind-
ing results in RIP2 inhibition [22]. Critical amino acids
for the NOD2/RIP2 binding have been found in both
CARDs [30] suggesting a activation of RIP2 by those
part of the second CARD which are truncated in
NOD2-S. There is a similar example for a tandem
CARD signaling molecule. The retinoic acid-inducible
gene-I protein (RIG-I) recognizes viral RNA and initi-
ates an antiviral signaling cascade [31]. Upon viral infec-
tion both N-terminal RIG-I CARDs are needed for
proper interaction with downstream signaling partners
like MAVS or Cardif. Interestingly, while the
first CARD is essential for binding of TRIM25
(tripartite motif protein 25) the second one enables
Figure 6 Cytosolic localization of NOD2-C2. COS7 and HEK293E cell were transiently transfected with Flag-tagged NOD2-C2 construct and
after 24 h immunostained with anti-Flag antibody.
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NOD2 signaling requires the interaction with the kinase
RIP2, further analyses should be addressed to potential
CARD post-translational modifications like phosphoryla-
tion using NOD2-C2 as biologically relevant experimen-
tal systems. In line with NOD2-S, a RIG-I splice variant
with a short deletion in the first CARD acts as an endo-
genous inhibitor of RIG-I signal transduction, possibly
providing a negative-feedback inhibition or fine-tuning
mechanism [31].
Whatever the NOD2-C2 functions in vivo explicitly
are, our in vitro findings point to a sub-functionalization
of NOD2 isoforms in innate immunity. Similar to
NOD2-S, NOD2-C2 abolishes the stimulatory effect of
MDP, but does not significantly decrease NOD2-
mediated NF-Ba c t i v i t yi nt h ea b s e n c eo fM D P .W e
assume a NOD2-C2/NOD2 interaction preventing the
NOD2 self oligomerization that followed MDP stimula-
tion and subsequent RIP2 activation as it has been
described for NOD2-S [22]. This inhibition is compen-
sated by the ability of NOD2-C2 to activate NF-Bi na
MDP-independent manner. Since NOD2-C2 shares the
vast majority (163) of its 205 amino acids with NOD2-S,
similar to NOD2-S/NOD2 a potential for NOD2-C2/
NOD2 interaction exists. Additionally, we observed
NOD2-C2 cytosolic localization as it has been described
for NOD2. Although NOD2 may also be associated with
the plasma membrane [10,12-14], this is not expected
f o rN O D 2 - C 2d u et ot h ea b s e n c et h eC O O H - t e r m i n a l
domain of NOD2 required for membrane association
[10]. Nevertheless, a potential interaction of NOD2-C2
with other membrane-associated molecules like CD147
or Erbin has already been assumed, since both NOD2
CARDs are needed for sufficient interaction. CD147 is a
regulator of cellular migration, differentiation and
inflammatory processes [14] and Erbin potentially regu-
lates NOD2 and is involved in cell polarity, receptor
localization and regulation of MAPK pathways [32].
This suggests that NOD2-C2 features a multi-facetted
interaction potential and to date unknown functional
spectrum. NOD2-C2 transcripts are predominantly
expressed in leukoyctes, cells of the immune system
defending the host against both infections and pathogen
materials. Together with NOD2-C2s ability to activate
NF-B in a MDP-independent manner we assume that
N O D 2 - C 2a c t sa sa ne n d o g e n o u si n d u c t o ro fab a s a l
immune response to handicap pathogen invasion.
Expression levels of NOD2-C2 transcripts are low but
consistent in human tissues and LCLs (about 1% of all
NOD2 transcripts when inspecting exons 2-4 by quanti-
tative RT-PCR). Nevertheless, overexpression of an arti-
ficial NOD2 tandem CARD construct was toxic for
HEK293T cells [32]. This agrees with the low amounts
of NOD2-C2 transcripts in LCLs. It is plausible that
NOD pathways could turn on apoptosis pathways (such
as caspase induction), but the final outcome of cell
death would be generally masked by the overriding anti-
apoptotic power of NOD-mediated activation of NF-B
pathways. Nevertheless, it was shown that Nod1-depen-
dent apoptosis is a caspase 8-mediated event and that
apoptosis requires RIP2 [33]. Therefore, further studies
have to be performed to reveal NOD2-C2s involvement
in cell death. Interestingly, the expression of the NOD2-
C2 transcript in LCLs was significantly different for all
three possible rs2076085 genotypes with 2-fold higher
expression of the C allele compared to G. The observed
allele-preferential expression of NOD2-C2 transcripts
allows speculation about potential implications with
respect to inflammatory abnormalities like CD. So far,
genome-wide association studies did not uncover
rs2067085 being associated with CD or ulcerative colitis
(UC). Juval and colleagues found that rs2067085 allele
and genotype frequencies did not differ between con-
trols and UC patients [34]. Nevertheless, homozygous G
individuals are not common in HapMaps [35] CEU
(Utah residents with Northern and Western European
ancestry from the CEPH collection) population (17,2%)
and are under-represented in their Caucasian cohorts
(with 8% in controls and 6,3% in UC patients). Interest-
ingly, this genotype is rare in Africans YRI (YRI - Yor-
uba in Ibadan, Nigeria, 3.4%) and totally missing in
Asians (JPT - Han Chinese in Beijing, China and HCB -
Japanese in Tokyo, Japan). Thus, studies on a larger
population of European ancestry may reveal an associa-
tion of the minor rs2067085 allele and disease driven by
chronic inflammation.
The mechanistic impact on splicing of the synon-
ymous SNP rs2067085 (C/G, Ser/Ser) is not known. Its
localization 7 nucleotides upstream of the exon/intron
boundary let us speculate about potential splice regula-
tory functions [36]. Although the ESE finder predicts
different splicing factor binding sites for both SNP
alleles [31], we found no association with the inclusion
or skipping of the downstream exon 3. On the other
hand, exon 3a inclusion is only observed in transcripts
c a r r y i n ge x o n3 .A l t h o u g he x o n3 ai si nt h ep r i m a r y
transcript 10 kb downstream of exon 2, it derives twice
as often from the transcribed C in comparison to the G
allele of rs2067085. It may well be that inclusion of
exon 3a depends on an upstream splicing event as it
has been reported for the thrombopoietin gene where
the recognition of the donor and acceptor sites of an
intron requires spliceosome assembly on upstream
splice sites [37].
Similarly, efficient splicing of NF1 is guided by distant
sequence features [38]. No reports that could explain
our finding are available. Thus, detailed studies, for
instance using minigene constructs, may provide further
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potentially affecting gene expression, like promoter
SNPs, has not been tested. Nevertheless we have shown
by 5′RACE that NOD2-C2 exclusively contains the
recently identified exon 1a [29] and is therefore tran-
scribed from the alternative NOD2 promoter, whereas
transcription of the canonical exon 1 is regulated by an
NF-B-dependent promoter. This may lead to tissue-
specific and context-dependent NOD2 transcript isoform
patterns [29], with respect to independently regulated
expression of NOD2 and NOD2-C2 transcripts in the
context of inflammatory signaling. Although there is a
low basal NOD2 expression in chimpanzee LCLs, we
found NOD2-C2 transcripts being expressed too (data
not shown). This is surprising since a number of genes
involved in the inflammatory response - APOL1,
APOL4, CARD18, IL1F7, IL1F8 - are entirely deleted
from chimp genome [39]. In humans, APOL1 is involved
in resistance to the parasite that causes sleeping sickness
[40], while IL1F7 and CARD18 play a role in regulating
inflammation. Therefore, there has to be a different reg-
ulations of these processes in chimpanzees [41-43]. In
this context the existence of NOD2-C2 transcripts at
low levels similar to the situation in humans supports
the assumed importance in basal NF-B activation.
Due to the lack of suitable antibodies for C-terminal
truncated NOD2 isoforms, we could not detect endo-
genous NOD2-C2 in vivo. In particular, we obtained
irresolvable multiple bands employing Western blotting
with commercial antibodies raised against N-terminal
peptides. Formally, the NOD2-C2 transcript isoform
appears as a target for nonsense-mediated mRNA decay
(NMD) as it harbors a premature stop codon within
exon 3a followed by at least one exon/exon junction
[44]. The exceptionally long fourth exon (1.8 kb) ham-
pers the analysis of downstream transcript structure, but
increases the possibility to overcome NMD e.g. by alter-
native polyadenylation sites. Furthermore, the consistent
transcript levels and the evidence for NOD2-S protein
translation [22] indicate that NMD or other mechanisms
in transcripts with premature stop codons (e.g. negative
regulation of nuclear export or translation) may not play
a functional role for NOD2-C2 transcripts [45]. Interest-
ingly, corresponding truncated variants of R genes in
plants also seem to escape NMD [46]. Thus, future stu-
dies have to elucidate whether NOD2-C2/-S transcript
isoforms belong to the class of NMD escapers.
Conclusions
NOD2 transcripts carrying an alternative exon down-
stream of exon 3 (exon 3a) are the endogenous equiva-
lents of a previously described in vitro construct with
the putative protein composed of only the two N-term-
inal CARDs. This protein form (NOD2-C2) activates
NF-B independent of an MDP stimulus and is a poten-
tial regulator of NOD2 signaling.
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